转移性复发性宫颈癌复发部位的预后意义
该回顾性研究纳入2000—2013年1322例原发性宫颈癌中205例放疗后复发患者,分析复发部位与生存关系。远处淋巴结或肺实质单独复发(A型DO)预后显著优于其他部位,5年总生存率44.8%。
要点
- 远处淋巴结或肺实质单独复发者预后最佳,占全部复发的36%。
- A型DO组5年总生存率44.8%,盆腔组12.6%,B型DO组6.8%。
- A型DO组83.8%接受积极挽救治疗(AST),但需前瞻性试验验证生存获益。
核心结论
- 存在预后良好的复发亚组A型DO,即仅远处淋巴结复发或仅肺实质复发。
- A型DO患者接受挽救治疗后5年总生存率显著高于其他复发部位患者。
研究设计与样本
- 回顾性研究,从2000至2013年1322例原发性宫颈癌中纳入205例初次或辅助术后放疗后复发患者。
主要发现
- 复发模式:单纯远处复发最常见(59.5%),其次为混合复发(21.5%)、中央复发(宫颈或阴道残端,10.7%)和盆腔复发(盆腔淋巴结或盆壁,8.3%)。
- A型DO组占全部复发的36%,其中83.8%接受了AST。
- 5年总生存率:A型DO组44.8%,盆腔组12.6%,B型DO组6.8%。
关键数值与推荐
- AST定义为不仅缓解症状,还通过手术切除局部复发灶、转移灶切除或转移灶定向照射联合化疗以消融复发肿瘤的挽救治疗。
- A型DO定义为仅远处淋巴结复发或仅肺实质复发。
临床怎么用
- 对仅远处淋巴结或仅肺实质复发的宫颈癌患者,可考虑积极挽救治疗以改善生存。
局限性
- 回顾性研究设计,需前瞻性试验验证AST能否改善A型DO组生存。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The clinical characteristics and outcomes of patients with metastatic recurrent cervical cancer remain poorly understood. The goals of the present study were to investigate the survival outcomes according to the recurrence site in a large cohort of cervical cancer patients. METHODS AND MATERIALS: Of 1322 patients with primary cervical cancer from 2000 to 2013, 205 with recurrence after primary or adjuvant postoperative radiation were enrolled retrospectively. Aggressive salvage therapy (AST), which was defined as salvage therapy that aimed not only to relieve symptoms but also to ablate recurrent tumors by the single or combined application of surgical resection of local recurrence, metastasectomy, or metastasis-directed irradiation, followed by chemotherapy, was performed according to our institutional guidelines. The patterns of recurrence, application rate and mode of AST, and survival outcomes were evaluated retrospectively under approval from the institutional review board. RESULTS: Regarding the pattern of recurrence, distant-only (DO) recurrence was most common (59.5%), followed by combined (21.5%), central (cervix or vaginal stump; 10.7%), and pelvic (pelvic lymph nodes or pelvic side wall; 8.3%) recurrence. Two subgroups (distant lymph nodes and lung parenchyma) of the DO group demonstrated remarkably good prognosis and were categorized as type A DO; the other subgroups were labeled type B DO. Patients with type A DO recurrence constituted 36% of all recurrences and 83.8% of them received AST. The 5-year overall survival rates were significantly greater in the type A DO group than in the other groups (44.8% in the type A DO group, 12.6% in the pelvic group, and 6.8% in the type B DO group). CONCLUSIONS: We identified a patient subgroup with favorable outcomes after salvage therapy, type A DO, defined as recurrence in the distant lymph nodes only or in the lung parenchyma only. A future prospective trial is needed to investigate whether AST improves survival in this group.
引用
- Kim TH, Kim MH, Kim BJ, et al. Prognostic Importance of the Site of Recurrence in Patients With Metastatic Recurrent Cervical Cancer. Int J Radiat Oncol Biol Phys. 2017. PMID: 28721896. doi:10.1016/j.ijrobp.2017.03.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。